↓ Skip to main content

Oncotarget

Article Metrics

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

Overview of attention for article published in Oncotarget, May 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
1 news outlet
twitter
1 tweeter
patent
4 patents

Citations

dimensions_citation
206 Dimensions

Readers on

mendeley
223 Mendeley
Title
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
Published in
Oncotarget, May 2015
DOI 10.18632/oncotarget.4183
Pubmed ID
Authors

Talia Golan, Elina Zorde Khvalevsky, Ayala Hubert, Rachel Malka Gabai, Naama Hen, Amiel Segal, Abraham Domb, Gil Harari, Eliel Ben David, Stephen Raskin, Yuri Goldes, Eran Goldin, Rami Eliakim, Maor Lahav, Yael Kopleman, Alain Dancour, Amotz Shemi, Eithan Galun

Abstract

The miniature biodegradable implant siG12D-LODER™ was inserted into a tumor and released a siRNA drug against KRAS(G12D) along four months. This novel siRNA based drug was studied, in combination with chemotherapy, as targeted therapy for Locally Advanced Pancreatic Cancer (LAPC). An open-label Phase 1/2a study in the first-line setting of patients with non-operable LAPC was initiated. In this study patients were assigned to receive a single dose of siG12D-LODERs, in three escalating dose cohorts (0.025mg, 0.75mg and 3.0mg). Gemcitabine was given on a weekly basis, following the siG12D-LODERTM insertion, until disease progression. The recommended dose was further examined with modified FOLFIRINOX. The follow up period was eight weeks and survival until death. Fifteen patients with LAPC were enrolled. Among the 15 treated patients, the most frequent adverse events observed were grade 1or 2 in severity (89%); five patients experienced serious adverse events (SAEs). In 12 patients analyzed by CT scans, none showed tumor progression, the majority (10/12) demonstrated stable disease and two showed partial response. Decrease in tumor marker CA19-9 was observed in 70% (7/10) of patients. Median overall survival was 15.12 months; 18 month survival was 38.5%. The combination of siG12D-LODER™ and chemotherapy is well tolerated, safe and demonstrated a potential efficacy in patients with LAPC. NCT01188785.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 223 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 <1%
Germany 1 <1%
Brazil 1 <1%
Unknown 220 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 38 17%
Researcher 36 16%
Student > Bachelor 34 15%
Student > Master 26 12%
Other 14 6%
Other 30 13%
Unknown 45 20%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 54 24%
Medicine and Dentistry 34 15%
Pharmacology, Toxicology and Pharmaceutical Science 21 9%
Agricultural and Biological Sciences 19 9%
Chemistry 16 7%
Other 27 12%
Unknown 52 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2022.
All research outputs
#2,006,500
of 23,339,727 outputs
Outputs from Oncotarget
#847
of 14,401 outputs
Outputs of similar age
#26,992
of 267,465 outputs
Outputs of similar age from Oncotarget
#10
of 554 outputs
Altmetric has tracked 23,339,727 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,401 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,465 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 554 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.